Related Experiment Video
Updated: Jun 1, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Promising Anticancer Activity of Pyrazole Compounds against Glioblastoma Multiforme: Their Synthesis, In vitro, and
Kemal Alp Nalcı1, Cihat Mete2, Zeynep Demir2
1Department of Pharmacology, Faculty of Pharmacy, Van Yüzüncü Yil University, Van, Türkiye.
Background:
Glioblastoma Multiforme (GBM), a highly aggressive and prevalent brain cancer with a higher incidence in males, has limited treatment success due to drug resistance, inadequate targeting and penetration of cancer cells, and an incomplete understanding of its molecular pathways. GBM is a highly aggressive brain cancer with limited treatment options. This study investigates the anticancer potential of synthesized pyrazole compounds against GBM cells.
Methods:
A series of pyrazole derivatives were synthesized and tested for their efficacy against GBM using MTT assays. Molecular docking studies were conducted to explore the binding interactions of these compounds with GBM receptors.
Results:
Compounds 3 and 5 demonstrated significant anticancer activity, reducing cell viability more effectively than the control group. MTT assay results confirmed their potency. Molecular docking studies revealed strong binding interactions with GBM receptors, highlighting their potential as anticancer agents.
Conclusion:
The study evaluated the anticancer activity of synthesized compounds on human GBM cells, with compounds 3 and 5 showing the most promising results. Pyrazole 3 significantly reduced cell viability at high concentrations, while both pyrazoles 3 and 5 required higher doses to achieve substantial effects, as indicated by their IC50 values. Molecular docking studies confirmed strong binding interactions with the GBM receptor, and the pharmacokinetic properties suggest their potential as anticancer agents. These results highlight compounds 3 and 5 as candidates for further investigation.
Insights
Synthesized pyrazole compounds show promise against glioblastoma multiforme (GBM). Compounds 3 and 5 effectively reduced GBM cell viability and exhibited strong binding to GBM receptors, indicating potential as novel anticancer agents.
Area of Science:
- Medicinal Chemistry
- Oncology
- Molecular Biology
Background:
- Glioblastoma Multiforme (GBM) is an aggressive brain cancer with limited treatment options due to drug resistance and poor targeting.
- Current therapeutic strategies for GBM face challenges in effectively penetrating cancer cells and addressing underlying molecular pathways.
Purpose of the Study:
- To investigate the anticancer potential of newly synthesized pyrazole derivatives against human Glioblastoma Multiforme (GBM) cells.
- To explore the molecular interactions of these compounds with GBM-related receptors through computational methods.
Main Methods:
- Synthesis of a series of pyrazole derivatives.
- Evaluation of compound efficacy using MTT assays to determine cell viability.
- In silico molecular docking studies to analyze binding affinities with GBM receptors.
Main Results:
- Compounds 3 and 5 exhibited significant cytotoxic effects on GBM cells, outperforming the control group.
- MTT assays confirmed the potent anticancer activity of pyrazole derivatives 3 and 5.
- Molecular docking revealed strong binding interactions between compounds 3 and 5 and key GBM receptors.
Conclusions:
- Synthesized pyrazole compounds, particularly derivatives 3 and 5, demonstrate considerable anticancer activity against GBM.
- Strong molecular interactions and favorable pharmacokinetic properties suggest these compounds are promising candidates for further therapeutic development.
- Compounds 3 and 5 warrant further investigation as potential novel agents for glioblastoma treatment.
